Table 1.
Bacterial strains used in this study
| Strain | Relevant characteristic(s)a | Source or reference |
|---|---|---|
| E. coli TOP10 | F−mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL endA1 nupG | Invitrogen |
| S. aureus | ||
| NCTC 8325-4 | Wild type, derivative of NCTC 8325 cured of all known prophages | 33 |
| RN4220 | Restriction-deficient derivative of NCTC 8325-4 | 33 |
| 8325-4 Δspx mutant | Δspx | 34 |
| 8325-4 ΔclpX mutant | ΔclpX | 7 |
| 8325-4 ΔclpP mutant | ΔclpP | 7 |
| Newman | Human clinical isolate | 5 |
| LUSA1 | NCTC 8325-4 ΔyjbH::spc, Spr | This study |
| LUSA2 | Newman ΔyjbH::spc, Spr | This study |
| LUSA3 | RN4220 pCL25, Tcr | This study |
| LUSA4 | RN4220 pCL25_yjbIH, Tcr | This study |
| LUSA7 | Newman pCL25, Tcr | This study |
| LUSA8 | Newman pCL25_yjbIH, Tcr | This study |
| LUSA9 | Newman pCL25 ΔyjbH::spc, Spr Tcr | This study |
| LUSA10 | Newman pCL25_yjbIH ΔyjbH::spc, Spr Tcr | This study |
| B. subtilis | ||
| 1A1 | trpC2 | BGSCb |
| LUW272 | ΔyjbH::spc, Spr | 35 |
| LUW297 | spxΩpMUTIN2, Emr | 21 |
| LUW362 | spxΩpMUTIN2 amyE::spxBs spc, Emr Spr | This study |
| LUW400 | ΔyjbH::spc amyE::cat, Cmr Spr | This study |
| LUW428 | spxΩpMUTIN2 amyE::spxSA cat, Emr Cmr | This study |
| LUW448 | ΔyjbH::spc amyE::yjbHSA cat, Spr Cmr | This study |
| LUW421 | ΔyjbH::spc amyE::yjbHBS cat, Spr Cmr | This study |
| LUW442 | ΔyjbH::spc spxΩpMUTIN2 amyE::spxSA tet/pCW7_ yjbHSA, Spr Cmr Tcr Emr | This study |
| LUW458 | ΔyjbH::spc amyE::yjbHBS-Cys cat, Spr Cmr | This study |
| LUW454 | ΔyjbH::spc amyE::pCW101_ yjbHSA, Cys-free, Spr Cmr | This study |
a
All B. subtilis LUW strains are derivatives of 1A1 and thus carry the trpC2 auxotrophic marker. Apr, ampicillin resistance; Emr, erythromycin resistance; Kmr, kanamycin resistance; Spr, spectinomycin resistance; Cmr, chloramphenicol resistance; Tcr, tetracycline resistance.
b
BGSC, Bacillus Genetic Stock Center, Department of Biochemistry, Ohio State University, Columbus, OH.